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Photodynamic therapy (PDT) is an emerging treatment for various solid cancers. We recently reported 
that tumor cell lines and patient specimens from adult T cell leukemia/lymphoma (ATL) are susceptible 
to specific cell death by visible light exposure after a short‑term culture with 5‑aminolevulinic acid, 
indicating that extracorporeal photopheresis could eradicate hematological tumor cells circulating 
in peripheral blood. As a bridge from basic research to clinical trial of PDT for hematological 
malignancies, we here examined the efficacy of ALA‑PDT on various lymphoid malignancies with 
circulating tumor cells in peripheral blood. We also examined the effects of ALA‑PDT on tumor cells 
before and after conventional chemotherapy. With 16 primary blood samples from 13 patients, we 
demonstrated that PDT efficiently killed tumor cells without influencing normal lymphocytes in 
aggressive diseases such as acute ATL. Importantly, PDT could eradicate acute ATL cells remaining 
after standard chemotherapy or anti‑CCR4 antibody, suggesting that PDT could work together with 
other conventional therapies in a complementary manner. The responses of PDT on indolent tumor 
cells were various but were clearly depending on accumulation of protoporphyrin IX, which indicates 
the possibility of biomarker‑guided application of PDT. These findings provide important information 
for developing novel therapeutic strategy for hematological malignancies.
Photodynamic therapy (PDT) is a therapeutic modality that specifically kills target cancer cells through the 
combination of a photosensitizer and light irradiation. PDT is used for skin diseases such as actinic keratosis 
because it can be administered repeatedly and does not cause  scars1. In addition, PDT has also been studied for 
malignant diseases such as head and neck cancer, esophageal cancer, prostate cancer and bladder  cancer2–7. A 
natural amino acid, 5-aminolevulinic acid (5-ALA), is a precursor of protoporphyrin IX (PpIX) in the heme 
biosynthesis pathway. PpIX is a fluorescent photosensitizer that generates singlet oxygen (1O2) in cells exposed 
to visible light. PpIX selectively accumulates in tumor cells because of metabolic abnormalities. Since tumor cells 
are abnormal in the heme biosynthetic pathway, PpIX specifically accumulates in tumor cells. By this property, 
5-ALA is used for photodynamic diagnosis (PDD) and  PDT8,9. For malignant glioma and bladder cancer, intra-
operative visualization with 5-ALA can remove tumors more completely than without 5-ALA10,11. ALA-PDT has 
also been approved to treat the precancerous disease actinic  keratosis12. However, there are only a few studies on 
the application of ALA-PDT for hematological  malignancies13,14.
Adult T cell leukemia/lymphoma (ATL) is an aggressive T cell malignancy caused by human T cell leukemia 
virus type 1 (HTLV-1)15. ATL is classified into 4 clinical subtypes: acute, lymphoma, chronic, and  smoldering16. 
The acute and lymphoma types of ATL, which are considered aggressive ATL, have a dismal prognosis, mainly 
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because of resistance to a variety of cytotoxic  agents17–19. For aggressive ATL patients, allogeneic hematopoietic 
stem cell transplantation (HSCT) has a critical role in maintaining long-term  remission20–23. As a bridge to 
HSCT, patients need to receive intensive combination chemotherapy to reduce the tumor burden, however, 
many cases could become refractory to chemotherapy before transplant. In recent years, the efficacy of human-
ized anti-chemokine receptor 4 (CCR4) antibodies and immunomodulatory drugs such as lenalidomide have 
been approved and used in the treatment of aggressive  ATL24–27. However, the pretransplant use of anti-CCR4 
antibodies or lenalidomide could cause severe graft-versus-host disease (GVHD) after HSCT, and thus, it is dif-
ficult to use these drugs as a bridging therapy to  HSCT28,29. On the other hands, there are few treatment options 
for patients without indications for transplantation. These factors suggest that the efficient and safe treatment 
options for aggressive ATL are not yet sufficient.
We have previously shown that ALA-PDT could selectively kill ATL cell lines established from patients with 
acute-type ATL and also shown the dynamic changes in flow cytometry profiles during the onset and progres-
sion of ATL with patient specimens. Furthermore, 98.7% of ATL leukemic cell death in the chronic ATL patients 
could be induced with 10 min of visible light exposure, while 77.5% of normal PBMCs survived. Metabolomics 
analyses revealed that a specific stage of the metabolic pathway progressively deteriorated with HTLV-I infection 
and at the onset of  ATL30. Based on the basic findings, we are now in the stage of preparing clinical applications 
for this treatment. For preparing the clinical trial of ALA-PDT, it is necessary to identify the types and clinical 
stages of lymphoid malignancies those are the most promising targets for PDT effect. For this reason, in the 
current study, we obtained blood samples from patients with ATL at various clinical and therapeutic stages, and 
investigated the effects of PDT on ATL cells. We also evaluated the susceptibility of ATL to ALA-PDT compar-
ing to other hematological malignancies including chronic lymphocytic leukemia (CLL), follicular lymphoma 
(FL) and Sézary syndrome.
Results
PDT efficiently induces necrosis of ATL cells from patient blood. To evaluate the effect of ALA-
PDT on cancer cells in patients with hematological malignancies, we established an in vitro experimental sys-
tem (Fig. 1A). In our previous paper, we confirmed that PpIX accumulation in tumor cell lines had reached at 
C. Pt.7ATL acute type D. Pt.8 ATL acute type
10
-1
10
0
10
1
10
2
10
3
0
30
60
90
120
10
-1
10
0
10
1
10
2
10
3
0
50
100
150
10
-1
10
0
10
1
10
2
10
3
0
100
200
300
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
0
500
1.0K
1.5K
2.0K
10
-1
10
0
10
1
10
2
10
3
0
500
1.0K
1.5K
10
-1
10
0
10
1
10
2
10
3
0
1.0K
2.0K
3.0K
4.0K
0.1
24.8
92.9
6.4
94.4
1.5 2.8
95.8
0.6
7.0
91.1
1.4
6.5
91.4
1.8
11.7
33.9
48.8
1.0
1.1
72.0
PpIX FVD
A
nn
ex
in
V
Shaded Irradiated
5-ALA
0mM
0.25mM
1mM
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
Before PDT After PDT
CADM1
C
D
7
CADM1
C
D
7
78.8 6.5
5-ALA 1mM
0.1
5.3
98.8
0.5
99.4
0.1 0.7
99.1
0.1
0.3
99.6
0.1
0.4
99.4
0.1
0.6
86.6
11.7
0.1
0.4
86.3
PpIX FVD
A
nn
ex
in
V
Shaded Irradiated
5-ALA
0mM
0.25mM
1mM
10
-2
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-2
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
Before PDT After PDT
CADM1
C
D
7
CADM1
C
D
7
84.3 12.0
5-ALA 1mM
Live CD4+ T cells Live CD4+ T cells
B. Pt.9 ATL acute type
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
0
100
200
300
400
500
10
-1
10
0
10
1
10
2
10
3
0
200
400
600
10
-1
10
0
10
1
10
2
10
3
0
200
400
600
800
1.0K
0.1
13.4
91.2
3.1
94.5
1.0 1.4
97.4
0.5
3.3
94.8
1.0
2.8
93.2
0.8
3.6
78.9
16.4
2.1
11.3
83.7
PpIX FVD
A
nn
ex
in
V
Shaded Irradiated
5-ALA
0mM
0.25mM
1mM
Live CD4+ T cells
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
10
-1
10
0
10
1
10
2
10
3
Before PDT After PDT
CADM1
C
D
7
CADM1
C
D
7
91.5 50.0
5-ALA 1mM
CD4+ CADM1+ ATL cells CD4+ CADM1+ ATL cells CD4+ CADM1+ ATL cells
Visible Light
Irradiattion
(66 min)
5-ALA
exposure
incubation
(4 hours)
Wash
PBMC
purification
Before PDT
Analysis
After PDT
Analysis
A
Figure 1.  PDT induces necrosis of ATL cells from patient blood. (A) The experimental procedure of PDT is 
shown. PBMCs were purified from peripheral blood samples and then were incubated in the presence of various 
concentrations of 5-ALA for 4 h. After the removal of 5-ALA, PBMCs were irradiated with 630 nm visible light 
for 1 h. Samples were promptly analyzed by flow cytometry. (B) Analyses of three patients with ATL are shown. 
Live  CD4+ T cells show the population of  CD4+CD7-CADM1- cells. ATL cells were identified by CD4, CD7 and 
CADM1 as shown in the upper panels of Fig. 1B-D. PpIX accumulation on ATL cells after incubation is shown 
in the lower left panels. Apoptosis and necrosis of tumor cells after PDT are shown in the lower right panels.
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4 h after ALA addition into the culture media, while normal cells did not accumulate PpIX in the same time 
 period30. Based on the data, we treated tumor cells for 4 h in the current study. Purified PBMCs were incubated 
with various concentrations of 5-ALA for 4 h and then exposed to visible light for 1 h. Cell viability was evalu-
ated before and after the ALA-PDT procedure by flow cytometry.
We stained surface CD4, CD7 and CADM1 together with Annexin V and FVD.  CD4+ T cells were subdivided 
into 3 subpopulations based on the expression pattern of CD7 and Cell adhesion molecule 1 (CADM1). Previ-
ous studies reported that CADM1 is expressed in HTLV-1-infected cells and that the downregulation of CD7 
in CADM1-positive cells indicate clonal evolution from an asymptomatic carrier (AC) to  ATL31–33. Therefore, 
normal cells, HTLV-1-infected premalignant cells and HTLV-1-infected ATL cells are efficiently enriched in the 
 CD7+CADM1- fraction, in the  CD7+CADM1+ fraction and in the  CD7-CADM1+ fraction, respectively. In each 
population, cells that did not express either Annexin V or FVD were defined as “live cells” in this study. First, 
 CD4+Annexin  V-FVD- live cells were gated and examined for the expression of CD7 and CADM1 (Fig. 1B–D). 
In the upper panels of Fig. 1B–D, tumor cells in the live cell gate were reduced after the ALA-PDT procedure in 
all 3 cases. In each case, tumor cells in the live cell gate decreased from 91.5 to 50.0% in patient 9 (Pt.9), from 
78.8 to 6.5% in Pt.7, and from 84.3 to 12.0% in Pt.8. In the lower left panels of Fig. 1B–D, the accumulation of 
PpIX in tumor cells was evaluated. PpIX accumulated according to the concentration of 5-ALA in all 3 ATL acute 
type cases. In the lower right panels of Fig. 1B–D, the number of necrotic cells did not increase regardless of the 
concentration of 5-ALA in the shaded state, but after light irradiation, the number of FVD-positive necrotic cells 
markedly increased according to the concentration of 5-ALA. Of note, the efficacy of PDT was also observed in 
a patient with prior anti-CCR4 antibody treatment (Fig. S1). These findings suggest that cancer cells from the 
ATL acute type are very susceptible to necrosis by this ALA-PDT procedure.
The effect of PDT on indolent lymphoid malignancies varies depending on the levels of tumor 
cell activation. To evaluate the effect of ALA-PDT on various hematological malignancies other than 
aggressive ATL, we obtained peripheral blood samples from patients with indolent hematological malignancies 
as shown in Table 1. In each sample, tumor cell were identified by the tumor-specific surface antigens (Table 1) 
and evaluated the tumor cell death after PDT. The flowcytometric gating and evaluation strategy in cases of 
HTLV-1 AC, chronic ATL and follicular lymphoma (FL) are shown in Fig. 2A–C. Our results indicated that 
the responses of PDT to these tumors were highly variable. For example, in a case of HTLV-1 AC (Pt.11), PDT 
exposure induced approximately 30% of the  CD4+CADM1+ cells to undergo apoptosis or necrosis (Fig. 2A). In 
contrast, the percentage of tumor cells in the live cell gate was not reduced after the PDT procedure in Pt.12 and 
Pt.2 (Fig. 2B,C).
We examined the expression of Ki-67 in tumor cells and the serum lactate dehydrogenase (LDH) levels of 13 
patients and compared them among the following three groups; aggressive ATL (n = 4), HTLV-1 AC and indolent 
ATL (n = 4), and other lymphoid malignancies (n = 5) (Fig. 2D). The tumor cells of aggressive ATL were more 
proliferative than those of other diseases. In ATL patients, the concentration of serum soluble IL-2 receptor (sIL-
2R) was relatively higher in patients with aggressive ATL than in patients with indolent ATL patients (Fig. 2E,F). 
In the analysis of overall patients combined from groups of acute ATL, chronic ATL and HTLV-1 carrier, there 
Table 1.  Patient characteristics. Percentage of tumor cells were counted on microscopic examination. Ly 
lymphocytes, PB peripheral blood, FL follicular lymphoma, CLL chronic lymphocytic lymphoma, SS sezary 
syndrome, AC asymptomatic carrier, BM bone marrow, CNS central nervous system, LN lymph node, 
PUVA psoralen plus ultraviolet A, NBUVB narrow band UVB, RF rituximab/fludarabine, RB rituximab/
bendamustine, OFA ofatumumab, FB fludarabine/bendamustine, MOG mogamulizumab.
Pt. No Age sex disease clinical stage organ involved WBC (/μl)
% Ly 
(PB)
% tumor 
cells (PB) LDH sIL-2R Prior treatment
Response to prior 
treatment tumor cells %Ki-67+ of tumor cells normal cells
%Ki-67+ of 
normal cells
Other 
lymphoid 
malignancies
2 70F FL StageIV BM 2570 74.5 74.5 170 8731
RF
RB
Bendamustin
PR CD19+IgLammda+ – CD19+IgKappa+ –
4 61F CLL Rai:II,Bient:A BM 64,260 91.0 91.0 203 607 Fludarabine Ibrutinib PR CD19
+CD20+cells – CD19+CD20-CD23- –
5 66F CLL Rai:I,Bient:B BM 24,360 83.5 83.5 169 541
RF 6cycle
Ofatumumab 12cycle
FB 6cycle
SD CD19+CD20+cells 1.5 CD19+CD20-CD23- 0.2
3 77 M SS Stage IVA SkinBM 16,710 14.0 30.5 400 2551 New-Onset NA CD3
dimCD4– – CD3
+CD4+
CD3+CD4- –
13 74 M SS StageIVB Skin 17,280 6.5 24.0 315 5890 Non-Treated NA CD3+CD4+CCR4+ 9.0 CD3+CD4+CCR4- 13.3
HTLV-1
AC
10 41 M HTLV-1 AC NA 7,400 37.0 0.0 186 315 Non-Treated NA CD4+CADM-1+ 18.6 CD4+CD7+CADM-1- 5.4
11 39F HTLV-1 AC NA 3,930 38.5 3.5 212 659 Non-Treated NA CD4+CADM-1+ 18.0 CD4+CD7+CADM-1- 1.3
Chronic
ATL
6 65F ATL Chronic Skin 7430 11.5 3.0 176 1323
Etretinate
PUVA
NBUVB
SD CD4+CADM-1+ 26.6 CD4+CD7+CADM-1- 4.5
12 50F ATL Chronic SkinBreast 1350 87.0 2.0 203 1812 mLSG15 1cycle NA CD4
+CADM-1+ 0.5 CD4+CD7+CADM-1- 0.3
Aggressive
ATL
1 60F ATL Acute BMLN 2610 12.0 0.0 273 1494
MOG 2cycle
mLSG15 3cycle PR CD4
+CADM-1+ – CD4+CD7+CADM-1- –
9 55 M ATL Acute Skin 30,020 4.3 61.3 471 29,360 Non-Treated NA CD4+CADM-1+ 35.3 CD4+CD7+CADM-1- 1.9
7 39 M ATL Acute
BM
CNS 7500 6.0 6.3 257 28,481 New-Onset NA CD4
+CADM-1+ 64.7 CD4+CD7+CADM-1- 2.9
5340 8.0 1.0 228 3313 VCAP + AMP 1cycle PR CD4+CADM-1+ 73.0 CD4+CD7+CADM-1- 4.7
8 69F ATL Acute
Skin
BM
CNS
38,170 14.0 62.0 350 5264 New-Onset NA CD4+CADM-1+ 47.3 CD4+CD7+CADM-1- 6.9
1900 19.0 21.5 218 1196 mLSG15 PR CD4+CADM-1+ 18.9 CD4+CD7+CADM-1- 7.1
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was a positive relationship between % Ki-67 and % dead cells after PDT, however, in the analysis of each patient 
group, there was no correlation between the parameters. (Fig. 2F).
ALA‑PDT eradicates tumor cells but not normal lymphocytes from patients with aggressive 
ATL. The effects of ALA-PDT on tumor cells and normal cells in the examined 13 patients were summa-
rized in Fig. 3. Treated cells were examined for the expression of Annexin V and FVD, and the components of 
Annexin  V-FVD- live cells were calculated. As for aggressive ATL, the percentage of dead cells increased and 
the percentage of tumor cells decreas ed in the irradiated state with ALA-PDT. The effect was dependent on the 
concentration of 5-ALA (Fig. 3A). HTLV-1 AC and chronic ATL patient specimen showed the similar dose-
dependent decrease of survival leukemic cell percentage after PDT except for one specimen of chronic ATL 
(Pt.6), which was received skin directed therapies. However, tumor killing activity of PDT treatment was not so 
strong as that of acute ATL cases. As for other lymphoid malignancies, there were no differences in the compo-
nents in terms of the amount of 5-ALA or visible light irradiation (Fig. 3B,C).
We calculated the relative survival ratio to compare the effect of ALA-PDT on normal cells and tumor cells 
under each condition. The definition of normal cells and tumor cells by cell surface markers are shown in Table 1. 
For other lymphoid malignancies, there were no differences in the relative survival ratios of normal and tumor 
cells in each condition (Fig. 3F). For aggressive and indolent ATL, the relative survival ratio was the lowest for 
irradiated tumor cells after incubation with 1 mM 5-ALA. In contrast, the relative survival ratio of normal cells 
in three disease categories was not influenced by ALA-PDT (Fig. 3A–C), suggesting that ALA-PDT could spare 
normal cells and selectively kill tumor cells.
The cytolytic effects of PDT on ATL cells are depending on PpIX accumulation. We evaluated 
PpIX accumulation in  CD4+CD7-CADM1+ ATL cells in each sample by measuring mean fluorescence intensity 
(MFI). As shown in Fig. 4A, PpIX accumulation increased in an ALA dose-dependent manner both in a HTLV-1 
AC and in an acute ATL patient. Importantly, there was a significant linear association between the PpIX accu-
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Figure 2.  The effect of PDT on indolent lymphoid malignancies was limited in case PpIX accumulation was 
not sufficient. (A)–(C) Analyses of three patients with HTLV-1-AC, chronic ATL and FL are shown. Tumor cells 
were identified as  CD4+CADM1+ cells (A), (B), and as  CD19+Igλ+ cells in FL (C). PpIX accumulation on tumor 
cells after incubation is shown in the lower left panels. Apoptosis and necrosis of tumor cells after PDT are 
shown in the lower right panels. (D) The percentages of Ki-67 expression on tumor cells (left) and serum LDH 
levels (right) from patients with aggressive ATL or AC and Chronic ATL or other lymphoid malignancies. (E) 
Serum sIL-2R levels from patients with aggressive ATL or AC and Chronic ATL. (F) Correlation between Ki-67 
expression in tumor cells before ALA-PDT and % Annexin V and/or FVD positive cells after ALA-PDT (5-ALA 
1 mM). Data are expressed as the means +/− SEM.
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17237  | https://doi.org/10.1038/s41598-020-74174-x
www.nature.com/scientificreports/
mulation in tumors and the killing effect by PDT, suggesting that the cytolytic effects of PDT on ATL cells are 
depending on PpIX accumulation (Fig. 4B).
ALA‑PDT is effective for residual ATL cells after conventional therapy. In patients with aggres-
sive ATL, the effect of ALA-PDT on chemotherapy-resistant ATL cells that remained after the initial induction 
chemotherapy was examined (Fig.  5). Two patients with aggressive ATL and one patient with chronic ATL 
received the standard induction chemotherapy for ATL, which consisted of the following regimens: vincristine, 
cyclophosphamide, doxorubicin and prednisone (VCAP); doxorubicin, ranimustine and prednisone (AMP); 
and vindesine, etoposide, carboplatin and prednisone (VECP) (VCAP‐AMP‐VECP; mLSG15)17. The clinical 
course of each patient is shown in the lower panels of Fig. 5A,B. In Pt.7 and Pt.8, 5.9% and 61.7% of the  CD4+ 
T cells showed the  CD7-CADM1+ phenotype and were considered to be chemotherapy-resistant ATL popula-
tions, respectively, (Fig. 5A,B, upper panels). Our data demonstrated that the number of these cells was mark-
edly reduced after the ALA-PDT procedure. Most of the residual tumor cells after ALA-PDT showed an FVD-
expressing necrotic phenotype (Fig. 5A,B, middle panels). Importantly, in Pt.7, the expression of CCR4 in ATL 
cells decreased after chemotherapy. However, the CCR4-negative residual ATL cells as well as CCR4-positive 
ATL cells were also sensitive to ALA-PDT (Fig. 5A, middle panels). In contrast to Pt.7 and Pt.8, Pt.12 was clini-
cally diagnosed as indolent ATL with breast involvement, and the proliferative activity of the circulating ATL 
cells was still low (percentage of Ki-67-positive cells was 11.4%) at diagnosis (Fig. 5C, upper-left panel). In this 
patient, 13.6% of the  CD4+ T cells showed the  CD7-CADM1+ phenotype and were considered to be chemother-
apy-resistant, but this population was limited to partial reduction after ALA-PDT (13.6–11.4%). In Pt.7 and Pt.8, 
MFI value showing the degree of PPIX accumulation in tumor cells was high at 11.4 and 10.8, while in Pt.12, it 
was low at 3.33 (Table 2). These data suggested that susceptibility to ALA-PDT was associated with PpIX accu-
mulation in tumor cells not only before chemotherapy but also after chemotherapy.
Light exposure to ATL cells with subcellular localization of 5‑ALA induced active caspase‑3 
generation and mitochondria membrane potential changes. To further examine the biological 
mechanisms in which ALA-PDT can kill ATL cells, we performed the analyses with laser-scanning confocal 
microscopes and flow cytometry. First, we incubated TLOm1 cells in the presence of 5-ALA and examine the 
localization of PpIX in cells (Fig. S2). The result confirmed that PpIX is accumulated inside ATL cells and mainly 
localized to mitochondria. Then, we exposed 5ALA-treated ATL cell to the light. Flow cytometry analysis indi-
cated mitochondria membrane depolarization (Fig. S3). Laser-scanning confocal microscope (LSM) analysis 
also demonstrated the depolarization of mitochondria membrane potential at the PpIX accumulated loci and 
apoptotic body formation in ATL cells after ALA-PDT (Fig. S4). Active caspase-3 was detected by LSM and flow 
cytometry after ALA-PDT treatments (Fig. S5). The distribution pattern of active caspase-3 was closely localized 
to that of PpIX. These data visually and quantitatively confirmed the apoptotic and/or necrotic effect of ALA-
PDT on ATL cells and supported our findings of the ALA-PDT effects on primary ATL cells from patient blood 
in the current study.
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Figure 3.  ALA-PDT eradicates tumor cells but not normal lymphocytes from patients with acute ATL. The 
effects of ALA-PDT on tumor cells and normal cells in the examined 13 patients were summarized. Calculation 
of relative survival ratio is described in method. (A)–(C) Relative survival ratio of normal cells in patients was 
shown in blue. (D)–(F) Relative survival ratio of tumor cells in patients was shown in red. Relative survival ratio 
of tumor cells from patients with aggressive ATL was significantly decreased according the concentration of 
5-ALA (D).
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Discussion
In this study, we examined the effect of ALA-PDT on ATL cells from freshly obtained peripheral blood. Our 
data clearly demonstrated that the ALA-PDT procedure exerts selective cytotoxicity for aggressive ATL cells 
and spares normal lymphocytes. The efficacy of ALA-PDT appeared to be dependent on PpIX accumulation 
of tumor cells. The results also showed that the ALA-PDT procedure eradicated chemotherapy-resistant tumor 
cells that remained after induction chemotherapy. These findings suggest the potential of ALA-PDT to act as 
a novel alternative treatment that can complement chemotherapy and HSCT for patients with aggressive ATL.
Basic and clinical studies on ALA-PDT have been mainly conducted on only solid  tumors31,32. The effect 
of ALA-PDT on hematopoietic tumors has been studied mainly using leukemia tumor cell lines. In leukemia 
tumor lines, 5-ALA induces the accumulation of PpIX, and light irradiation induces cell  death13,14. It was also 
reported that different types of hematological malignancies had different responses to ALA-PDT33. To explore 
the clinical application of ALA-PDT for ATL patients, we conducted experiments to investigate the efficacy of 
this procedure for primary ATL cells as well as other hematological malignancies.
We first examined the samples from patients with aggressive ATL (Fig. 1). The accumulation of PpIX in 
tumor cells was observed in an ALA dose-dependent manner. After PDT, the number of tumor cells efficiently 
decreased, and the majority of residual tumor cells showed an FVD-positive necrotic phenotype. The efficacy 
was similar to our previous experiments that used aggressive ATL cell  lines30, showing that ALA-PDT is effective 
for not only established cell lines but also primary ATL cells from patient blood.
We then checked the efficacy of ALA-PDT for tumor cells of various hematological malignancies other than 
aggressive ATL. We evaluated Ki-67 expression in tumor cells and showed that Ki-67 expression in tumor cells 
was associated with the treatment efficacy of ALA-PDT, suggesting that highly proliferating tumor cells were 
more susceptible to death than slowly proliferating tumor cells. Previous studies reported that healthy human 
lymphocytes had an increased accumulation of PpIX and experience more cell death by light irradiation when 
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Figure 4.  The cytolytic effects of PDT on tumor cells are depending on PpIX accumulation. PpIX accumulation 
on tumor cells defined by  CD4+CD7-CADM+ at each 5-ALA concentration (A). Correlation between MFI of 
PpIX in tumor cells and % Annexin V and/or FVD positive cells in tumor cells after ALA-PDT (B).
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activated by PHA or CD3/28  stimulation34,35. Our group also reported that the addition of CD3/28 stimulation 
increases the accumulation of PpIX and cell death of indolent ATL  cells30. These data suggest that ALA-PDT may 
require the additional priming procedure to indolent tumor cells for the efficient induction of cell death. %Ki-67 
of tumor cells may be useful as a surrogate marker to evaluate the levels of tumor cell priming.
In the current study, HTLV-1 AC and chronic ATL specimen did not show the efficient response against ALA-
PDT compared to acute ATL cases. It is apparently contradicting to our previous study, showing that ALA-PDT 
induced cell death in the most part of ATL cells in the chronic ATL patients, while major part of normal PBMCs 
 survived30. There are several possible causes for the discrepancy of the results between our previous and current 
study. First, the light source was different. Li-Na lamp was used in the previous study, and then we have developed 
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Figure 5.  ALA-PDT is effective for residual ATL cells after induction chemotherapy. Clinical course of three 
patients with ATL were shown. Live  CD4+ T cells show the population of  CD4+CD7-CADM1- cells. ATL 
cells were identified by CD4, CD7 and CADM1 as shown in the upper panels. Evaluation of cell death after 
ALA-PDT are shown in the middle panels. The clinical course is shown in the lower row. Triple IT intrathecal 
injection (methotrexate, cytarabine, prednisolone), VCAP vincristine, cyclophosphamide, doxorubicin and 
prednisolone, AMP doxorubicin, ranimustine and prednisolone, VCEP vindesine, etoposide, carboplatin, 
prednisolone, HD hemodialysis, DOC disturbance of consciousness, PSL prednisolone.
Table 2.  PpIX accumulation and relative survival ratio on normal and tumor cells. FL follicular lymphoma, 
CLL chronic lymphocytic lymphoma, SS sezary syndrome, AC HTLV-1 asymptomatic carrier, cATL chronic 
ATL, aATL acute ATL.
5-ALA 
(mM) Pt # Diagnosis
MFI of PpIX Relative Survival Ratio (%)
Normal cells Tumor cells
Normal cells Tumor cells
Shaded Irradiated Shaded Irradiated
0 0.25 1 0 0.25 1 0 0.25 1 0 0.25 1 0 0.25 1 0 0.25 1
Indolent 
Lymphoid 
malignancy
2 FL 0.12 0.22 0.13 0.23 0.32 0.40 100 88.0 43.7 119.6 108.7 43.5 100 113.8 113.0 98.5 117.0 97.4
4 CLL 0.19 0.19 0.19 0.17 0.17 0.17 100 94.1 99.9 95.8 85.3 91.8 100 94.7 90.4 69.8 59.6 64.5
5 CLL 0.20 0.20 0.19 0.17 0.17 0.17 100 95.6 87.5 98.9 95.3 92.2 100 95.2 91.9 84.4 91.5 89.2
3 SS 0.34 0.53 3.02 0.40 0.75 6.15 100 117.8 123.8 113.5 127.7 121.4 100 101.5 103.3 82.8 87.9 72.8
13 SS 0.26 0.58 2.21 0.23 3.20 12.80 100 105.5 99.9 96.7 114.6 109.9 100 101.9 97.7 95.1 97.4 57.4
HTLV-1 AC
10 AC 0.17 0.34 4.40 0.18 0.54 5.27 100 99.7 104.8 94.5 98.5 98.8 100 106.4 107.0 82.8 77.7 58.3
11 AC 0.20 1.21 3.97 0.16 1.44 6.71 100 97.0 100.5 99.9 90.9 98.7 100 109.6 98.2 103.6 85.2 55.7
Chronic 
ATL
6 cATL 0.19 0.24 0.24 0.28 0.29 0.29 100 110.6 108.3 97.6 106.4 108.3 100 92.9 100.9 89.8 92.8 100.7
12 cATL 0.46 0.74 3.11 0.39 1.04 3.33 100 102.9 104.3 94.1 96.3 99.7 100 95.9 91.0 115.2 110.5 79.1
Aggressive 
ATL
1 aATL 0.75 1.37 8.38 0.59 0.84 10.40 100 97.7 110.5 120.5 130.0 104.9 100 104.6 141.8 63.9 29.9 2.5
9 aATL 0.22 1.04 4.84 0.20 0.91 9.19 100 100.3 99.7 90.7 107.9 136.8 100 103.9 106.2 116.3 79.4 6.9
7 aATL 0.22 1.80 6.20 0.19 0.91 11.40 100 103.1 102.6 95.4 86.8 71.3 100 102.7 105.8 117.5 33.2 0.6
8 aATL 0.34 0.88 5.29 0.25 0.51 10.80 100 98.7 97.0 82.0 88.2 62.8 100 101.2 105.0 101.5 77.5 0.5
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light emitting diode (LED) light source apparatus for the clinical application of PDT. This LED light source was 
used for the present investigation. The spectrum characters of light source were slightly different between them, 
although both of them have strong peak of 630 nm. Second, light exposure condition was different. 45.0 mW/cm2 
light intensity was exposed for 10 min in the previous study, whereas 20.4 mW/cm2 light intensity was exposed 
for 1 h in the present study, Third, time of incubation with 5-ALA was different. The incubation time was 24 h 
in the previous study, and 4 h in the current study, respectively. Among them, time of incubation with 5ALA 
seems to be the most important factor which might affect PpIX accumulation. Our previous data suggested that 
indolent ATL and lymphoma cases showed slower accumulation of PpIX as compared to acute ATL, which may 
result in the insufficient accumulation in the short incubation time. We therefore consider that the current study 
does not necessarily indicate that PDT will not work on other tumors. The further optimization of treatment 
condition in the clinical setting may enable to apply ALA-PDT for indolent hematological diseases as well as 
aggressive  diseases30. For clinical application of PDT to hematological malignancies, the careful consideration 
of algorithms that can efficiently expose 5-ALA to tumor cells in vivo should be required.
To assess the toxicity of 5-ALA itself and ALA-PDT combination therapy on normal lymphoid cells, we 
examined the viability of normal cells after interventions with 5-ALA and PDT. For indolent lymphoid malig-
nant lymphomas, the viability of both tumor cells and normal cells was not strongly influenced by ALA-PDT 
(Fig. 3C,F). On the other hand, for ATL, PpIX accumulation and viability of tumor cells decreased in an 5-ALA 
dose-dependent manner, while PpIX accumulation and viability of normal cells was not influenced (Fig. 3A,B,D,E 
and Table 2). The viability of tumor cells more decreased in aggressive ATL than in indolent ATL at the same 
condition. These data showed the tumor-specific cytolytic effects of ALA-PDT especially in aggressive ATL, 
which is related to that tumor cells accumulated PpIX more than normal cells (Table 2). Of interest, the viability 
of normal cell was not affected even through normal cells still retain certain levels of PpIX accumulation. It may 
suggest that there are other underlying mechanisms that can rescue normal lymphocytes from PDT-induced 
cytotoxicity. However, in the clinical situation, normal lymphocytes are susceptible to the inflammatory environ-
ments and the immune activated lymphocyte may accumulate PpIX more than naive lymphocytes. In addition, 
we found that 5-ALA alone could affect normal cells even without light exposure (Pt.2), indicating 5-ALA itself 
may have influenced the normal cell survival (Fig. 3C and Table 2). Further mechanistic studies are warranted 
on the safety of ALA-PDT to confirm that the clinical application of this treatment would not affect normal cells.
We then investigated the importance of PpIX accumulation on the killing effect of ALA-PDT. Our data 
confirmed that PpIX accumulation is crucial for the PDT-induced tumor cell death. PpIX was more accumu-
lated in acute ATL than in indolent ATL in the present experimental setting. AC, smoldering ATL and chronic 
ATL have a heterogeneous clinical and biological backgrounds and presumably it explains the heterogeneity of 
PDT response for indolent ATL. It is again suggested that tumor cell priming and effective 5-ALA exposure are 
important in chronic ATL.
Last, we examined the effects of ALA-PDT on ATL cells after conventional induction chemotherapy to deter-
mine whether chemotherapy affects the effect of ALA-PDT and whether ALA-PDT can work on chemotherapy-
resistant cells. A previous study showed that multidrug-resistant leukemia cell lines had no cross-resistance to 
ALA-PDT36–38. Our data demonstrated that the efficacy of ALA-PDT was not affected by previous chemotherapy 
and that ALA-PDT could eradicate tumor cells that remained after initial chemotherapy. In addition, as we 
showed in the clinical course of Pt.7 cells (Fig. 5), ALA-PDT worked regardless of the presence or absence of 
CCR4 expression on tumor cells, suggesting PDT can work without cross-resistance to CCR4-antibody treat-
ment as well as to chemotherapy. These findings strongly support that ALA-PDT can be used together with other 
conventional therapies and that these therapies may complement each other.
In this study, we showed the direct effect of ALA-PDT on tumor cell death. In clinical settings, the extracor-
poreal circulation system is required to irradiate circulating tumor cells. Irradiated and dying tumor cells will 
return to systemic circulation. Many studies have shown that apoptotic tumor cells express the eat-me signal and 
provoke the immune-based anti-tumor response, including tumor-specific cytotoxic T lymphocytes (CTLs)39–42. 
By using a photopheresis system, ALA-PDT could directly kill tumor cells in peripheral blood, and the necrotic 
or apoptotic tumor cells returned in patients, which might enhance the systemic anti-tumor immune response. 
These findings indicate the possibility that PDT may function not only directly on intravascular tumor cells but 
also indirectly on extravascular tumor cells by invoking anti-tumor immune responses in the  host43,44. As a step 
toward clinical application of ALA-PDT to hematological cancer, the current study confirmed the direct-killing 
effect of ALA-PDT on the primary tumor cells. The future basic and clinical studies need to clarify the immune-
related effect by PDT-treated cells to develop this treatment method to the clinical level.
There are several limitations in this study. First, our analysis was performed on a small number of patient 
samples with limited diseases. The further accumulation of various cases will be important to define the efficient 
clinical application of this treatment. Second, we made experiments with only one setting for light intensity. 
Higher light intensity may have been able to induce cell death even in tumor cells with low PpIX accumulation, 
and inversely, lower light intensity may be enough to induce cell death in tumor cells with high PpIX accumula-
tion. Third, our research did not evaluate cell death other than apoptosis and necrosis. Cell death was defined 
in many  variations45. It has been reported that various cell death such as autophagy, necroptosis and ferroptosis 
were induced by  PDT46–49. Future studies will need to investigate the details of cell death by ALA-PDT. Fourth, 
all experiments in this study were performed in vitro. Further studies with different experimental systems might 
be required to resolve the differences between in vitro and in vivo situations. Finally, the effect of PDT on normal 
nonlymphoid cells, including neutrophils, erythrocytes, and platelets, has not been well studied. Particularly, 
erythrocytes will be strongly exposed to PDT in the clinical situation; thus, this effect should be determined in 
future studies.
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In conclusion, these results indicate that PDT using 5-ALA is a unique and distinct therapeutic approach that 
can be combined with conventional chemotherapy or other emerging therapies, such as anti-CCR4 antibodies, 
thus providing a novel option to efficiently control the disease status of aggressive ATL.
Methods
Patient characteristics. The laboratory studies described in this report were performed for 13 adult 
patients who were newly diagnosed with lymphoid malignancies at Okayama University Hospital. The patients 
had circulating cancer cells in the peripheral blood. All patients were enrolled in clinical research protocols 
approved by the Human Subjects Protection Committee of the Okayama University Hospital. Written informed 
consent was obtained from each patient prior to sample collection, and this study was in accordance with the 
Declaration of Helsinki. The clinical characteristics of these patients are summarized in Table 1. One patient 
had Follicular Lymphoma (FL), 2 patients had Chronic Lymphocytic Lymphoma (CLL), 2 patients had Sezary 
Syndrome (SS), 2 patients had HTLV-1 Asymptomatic carrier (AC), 2 patients had Chronic Adult T Cell Leu-
kemia (ATL), and 4 patients had Acute ATL. Follicular lymphoma, chronic lymphocytic leukemia and Sézary 
syndrome were categorized as indolent lymphoid malignancies.
Experimental conditions for PDT. Peripheral blood mononuclear cells (PBMCs) and nucleated cells 
(NCCs) were isolated from heparin-treated whole blood samples from the patients. 5-ALA (Sigma Aldrich, 
St Louis, MO) was diluted in pure water to make a 298-mM stock solution. The cells were incubated in culture 
medium containing 0, 0.25 and 1 mM 5-ALA at 37 °C for 4 h under light-shielded conditions. After careful wash 
with 5-ALA-free culture medium (RPMI containing FBS), the PBMCs and NCCs were then exposed to visible 
light for 66 min for the PDT experiments. The wavelength of the light used was 630 nm, and the light intensity 
was 20.4 mW/cm2; the light was delivered by a plate irradiation device (Otsuka Electronics, Osaka, Japan). The 
irradiated cells were analyzed by flow cytometry.
Flow cytometry. Cells in single-cell suspensions were isolated from irradiated samples. The cells were first 
incubated with directly conjugated monoclonal antibodies (obtained from BioLegend unless otherwise stated) 
and Fixable Viability Dye eFluor 780 (FVD) (Thermo Fisher Scientific) for 30 min at 4 °C. After 30 min of incu-
bation, the cells were washed twice and incubated with Annexin V PE for 15 min at room temperature. For some 
experiments, Annexin V labeling was not included.
The following antibodies were used: anti-human CD3 (FITC, clone OKT-3, Thermo Fisher Scientific), CD4 
(Pacific Blue, clone PRA-T4), CD7 (FITC, clone CD7-6B7), light chain κ (Pacific Blue, clone 2D1), CD19 (PE, 
clone HIB19), CD20 (Pacific Blue, clone 2H7), CD23 (FITC, clone EBVCS-5), CD194 (PE-Cy7, clone 1G1,BD 
Biosciences), light chain λ (FITC, clone MHL-38), and chicken anti-TSLC1/CADM1 antibodies (PE, Clone 
3E1,MBL International Corporation, MA, USA).
The cellular PpIX contents were measured at an excitation wavelength of 488 nm and an emission wave-
length of 655–730 nm. Cell viability was evaluated with the expression of Annexin V and FVD, each was used 
as a marker of apoptosis and necrosis, respectively. Cells that did not express either Annexin V or FVD were 
defined as “live cells”. “The relative survival ratio” was calculated as follows: relative survival ratio = percentage 
of Annexin  V-FVD- live cells at each condition/percentage of Annexin  V-FVD- live cells at 0 mM 5-ALA and 
light-shielded conditions.
The samples were analyzed on a MACSQuant flow cytometer (Miltenyi Biotec), and the data were analyzed 
with FlowJo software (Tree Star).
Statistical analysis. Student’s t-tests were used to assess the statistical significance between 2 groups, one-
way analysis of variance was used to assess the statistical significance between 3 groups, and two-way analysis 
of variance was used to compare more than 3 groups. P values < 0.05 indicated statistical significance. Pearson 
product-moment correlation coefficient was used for correlation analysis. All tests were two-sided with a sig-
nificance level of 0.05.
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